Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) CEO John Quisel sold 33,000 shares of the company's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $79.15, for a total value of $2,611,950.00. Following the completion of the sale, the chief executive officer owned 226,064 shares of the company's stock, valued at $17,892,965.60. This trade represents a 12.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Disc Medicine Price Performance
Shares of Disc Medicine stock opened at $80.20 on Wednesday. The stock has a market cap of $307.57 million, a P/E ratio of -12.19 and a beta of 1.00. The company has a debt-to-equity ratio of 0.09, a quick ratio of 24.14 and a current ratio of 24.14. The stock's fifty day moving average is $75.13 and its 200 day moving average is $69.89. Disc Medicine, Inc. has a one year low of $40.00 and a one year high of $99.50.
Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.71) by $0.17. Sell-side analysts anticipate that Disc Medicine, Inc. will post -6.61 earnings per share for the current year.
Institutional Trading of Disc Medicine
Several institutional investors and hedge funds have recently added to or reduced their stakes in IRON. Palo Alto Investors LP purchased a new position in Disc Medicine in the 2nd quarter worth approximately $30,473,488,000. Capstone Investment Advisors LLC purchased a new stake in Disc Medicine during the 2nd quarter valued at approximately $245,000. Bank of America Corp DE purchased a new stake in Disc Medicine during the 2nd quarter valued at approximately $9,882,000. Man Group plc bought a new stake in shares of Disc Medicine during the second quarter valued at approximately $1,092,000. Finally, Jupiter Topco LLC bought a new stake in shares of Disc Medicine during the second quarter valued at approximately $844,000. Institutional investors own 83.70% of the company's stock.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on the stock. HC Wainwright increased their target price on shares of Disc Medicine from $118.00 to $120.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Wall Street Zen raised shares of Disc Medicine from a "sell" rating to a "hold" rating in a report on Saturday, August 1st. Wedbush reiterated an "outperform" rating and issued a $88.00 price target on shares of Disc Medicine in a research report on Wednesday, June 10th. Morgan Stanley reissued an "overweight" rating and issued a $90.00 price objective on shares of Disc Medicine in a research note on Monday. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Disc Medicine in a research report on Friday, July 17th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Disc Medicine presently has a consensus rating of "Moderate Buy" and a consensus target price of $106.50.
Read Our Latest Report on Disc Medicine
Disc Medicine Company Profile
(
Get Free Report)
Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.
The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
